Use of darbepoetin alfa in European clinical practice for the management of chemotherapy-induced anaemia in four tumour types: Final data from the CHOICE study

Current Medical Research and Opinion

Volumn 28, Issue 7, 2012, Pages 1089-1099

  Aerts, J G ^a,b   Swieboda Sadlej, A ^c   Karanikiotis, C ^d   Labourey, J L ^e   Galid, A ^f   Wheeler, T ^g   Pujol, B ^h   Van Belle, S ⁱ  

^a AMPHIA HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d Euromedica Kyanous Stavros Hospital   (Greece)

^e Centre Hospitalier Antoine Gayraud   (France)

^f Hanusch KH ^*  (Austria)

^g AMGEN LTD   (United Kingdom)

^h AMGEN INC   (United States)

ⁱ GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Breast cancer; Chemotherapy induced anaemia (CIA); Colorectal cancer; Darbepoetin alfa (DA); European summary of product characteristics (SPC); Haemoglobin (Hb); Lung cancer; Ovarian cancer; Red blood cell (RBC) transfusion; Routine clinical practice

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAPECITABINE; FLUOROURACIL; HEMOGLOBIN; IRINOTECAN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXALIPLATIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL PRACTICE; COLORECTAL CANCER; ERYTHROCYTE TRANSFUSION; EUROPE; FEMALE; HUMAN; IRON THERAPY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; PRACTICE GUIDELINE; PROSPECTIVE STUDY; SOLID TUMOR; TREATMENT OUTCOME;

ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD TRANSFUSION; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; ERYTHROPOIETIN; EUROPE; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES;

EID: 84863612639     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.698602     Document Type: Article

References (27)

1. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-306 (Pubitemid 39348881)
2. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-34 (Pubitemid 29479929)
3. Repetto L. Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey. Crit Rev Oncol Hematol 2009;72:170-9
4. Welch RS, James RD, Wilkinson PM, et al. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer. Cancer J Sci Am 1995;1:261-6
5. Steurer M, Wagner H, Gastl G. Prevalence and management of anaemia in haematologic cancer patients receiving cyclic nonplatinum chemotherapy: results of a prospective national chart survey. Wien Klin Wochenschr 2004;116:367-72 (Pubitemid 38937753)
6. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002;100:2303-20
7. Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 2008;13(Suppl 3):33-6
8. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-20 (Pubitemid 34993871)
9. Hedenus M, Adriansson M, San MJ, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403 (Pubitemid 36951623)
10. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-14 (Pubitemid 43821788)
11. Amgen. Aranesp Summary of Product Characteristics. 23-3-2011
12. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-70 (Pubitemid 46127840)
13. Steinmetz T, Totzke U, Soling U, et al. Hemoglobin levels that trigger erythropoiesis-stimulating agent treatment decisions for cancer-associated anemia-examination of practice in Germany. Curr Med Res Opin 2008;24:2751-6
14. Barrett-Lee P, Bokemeyer C, Gascon P, et al. Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey. Oncologist 2005;10:743-57 (Pubitemid 41567288)
15. Bittner N, Kipkova A, MócikováH, et al. Current management of chemotherapy-induced anemia with darbepoetin alfa-the apriori study. J Clin Oncol 2011;29:Suppl e19723
16. Gascon P, Almenarez J, Artal A, et al. Management of lung cancer-associated anaemia: the Spanish Lung Cancer Anaemia Survey (SLCAS). Clin Transl Oncol 2011;13:328-34
17. Soeling U, Spohn C, Verpoort K et al. CORRECT, a web-based, observational study, showing that darbepoetin alfa is effective in treating chemotherapy-induced anaemia and improves quality of life in patients with breast or colorectal cancer. Eur J Cancer 2009;7:Suppl 185-6
18. Schwartzberg LS, Yee LK, Senecal FM, et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 2004;9:696-707 (Pubitemid 39546409)
19. Nitz U, Gluz O, Oberhoff C et al. Adjuvant chemotherapy with or without darbepoetin alpha in node-positive breast cancer: survival and quality of life analysis from the prospective randomized WSG ARA Plus trial. Cancer Res 2011;71:Suppl PD07-09
20. Senecal FM, Yee L, Gabrail N, et al. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly. Clin Breast Cancer 2005;6:446-54 (Pubitemid 43078901)
21. Pirker R, Ramlau RA, Schuette W, et al. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol 2008;26:2342-9
22. Ludwig H, Crawford J, Osterborg A, et al. Pooled analysis of individual patientlevel data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009;27:2838-47
23. Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010;102:301-15
24. Cantrell LA, Westin SN, Van Le L. The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not affect progression-free or overall survival. Cancer 2011;117:1220-6
25. Crawford J, Glaspy J, Vansteenkiste J et al. Use of erythropoiesis- stimulating agents (ESAs) in lung cancer patients: study-level and patient-level metaanalyses of safety outcomes. J Thorac Oncol 2010;5:Suppl 552-3
26. Van Belle SJ, Cocquyt V. Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol 2003;47:1-11 (Pubitemid 36802321)
27. Pongsanon K, Benjapibal M, Ruengkhachorn I. Prognostic significance of hemoglobin levels in patients with primary epithelial ovarian carcinoma undergoing platinum-based chemotherapy. Asian Pac J Cancer Prev 2011;12:131-6